Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-089 in Mild-to-Moderate Alzheimer's Disease
NCT00555204Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- Nov 2007
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pozanicline in Alzheimer's disease (AD) (7 arms), sponsored by Abbott Laboratories. Primary endpoint: Safety and Tolerability. Started Nov 2007; status: terminated.
02
Drugs
pozanicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00555204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00555204.